Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Trevi Therapeutics (TRVI) Long-Term Debt Repayments (2018 - 2023)

Trevi Therapeutics' quarterly Long-Term Debt Repayments came in at $7.7 million in Q2 2023, up 337.66% year-on-year from $1.8 million in Q2 2022, and up 337.66% quarter-over-quarter from $1.8 million in Q1 2023.

Trevi Therapeutics has reported Long-Term Debt Repayments for 3 years, with the latest figure at $7.7 million in Q2 2023.

  • For the quarter ending Q2 2023, Long-Term Debt Repayments rose 337.66% year-over-year to $7.7 million; the trailing twelve-month figure through Sep 2023 stood at $11.2 million (up 173.3% YoY), and the FY2022 full-year result was $5.8 million, changed N/A from the prior year.
  • Long-Term Debt Repayments for Q2 2023 stood at $7.7 million, up from $1.8 million in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $7.7 million in Q2 2023, with the low at $583000.0 in Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Trevi Therapeutics 2.02 Bn 1.85 Bn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2023 7.66 Mn
Jun 30, 2023 7.66 Mn
Mar 31, 2023 1.75 Mn
Mar 31, 2023 1.75 Mn
Dec 31, 2022 1.75 Mn
Dec 31, 2022 1.75 Mn
Sep 30, 2022 1.75 Mn
Sep 30, 2022 1.75 Mn
Jun 30, 2022 1.75 Mn
Jun 30, 2022 1.75 Mn
Mar 31, 2022 583,000.00
Mar 31, 2022 583,000.00
Sep 30, 2018 1,000.00
Sep 30, 2018 1,000.00
Jun 30, 2018 2.75 Mn
Jun 30, 2018 2.75 Mn
Mar 31, 2018 2.06 Mn
Mar 31, 2018 2.06 Mn